Literature DB >> 27546233

Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery.

Robert C G Martin1, Alan North Durham2, Marc G Besselink3, David Iannitti4, Matthew J Weiss5, Christopher L Wolfgang6, Kai-Wen Huang6.   

Abstract

Irreversible Electroporation (IRE) is used to treat locally advanced cancers, commonly of the pancreas, liver, kidney, and other soft tissues. Precise eligibility for IRE should be established in each individual patient by a multidisciplinary team based on comprehensive clinical, imaging, and laboratory assessment. Standardization of IRE technique and protocols is expected to improve safety, lead to reproducible outcomes, and facilitate further research into IRE. The present article provides a set of technical recommendations for the use of IRE in the treatment of locally advanced pancreatic cancer. J. Surg. Oncol. 2016;114:865-871.
© 2016 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  irreversible electroporation; pancreatic cancer; technique

Mesh：

Year:  2016        PMID： 27546233     DOI： 10.1002/jso.24404

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  26 in total

Review 1.  Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation.

Authors:  Salvatore Paiella; Matteo De Pastena; Mirko D'Onofrio; Stefano Francesco Crinò; Teresa Lucia Pan; Riccardo De Robertis; Giovanni Elio; Enrico Martone; Claudio Bassi; Roberto Salvia
Journal:  Transl Gastroenterol Hepatol       Date:  2018-10-26

Review 2.  Irreversible Electroporation of the Pancreas.

Authors:  Gabriel Chan; Uei Pua
Journal:  Semin Intervent Radiol       Date:  2019-08-19       Impact factor: 1.513

3.  Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.

Authors:  Mao Lin; Shuzhen Liang; Xiaohua Wang; Yinqing Liang; Mingjie Zhang; Jibing Chen; Lizhi Niu; Kecheng Xu
Journal:  J Cancer Res Clin Oncol       Date:  2017-09-04       Impact factor: 4.553

Review 4.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

5.  Molecular and histological study on the effects of non-thermal irreversible electroporation on the liver.

Authors:  Yanfang Zhang; Chenang Lyu; Yu Liu; Yanpeng Lv; Tammy T Chang; Boris Rubinsky
Journal:  Biochem Biophys Res Commun       Date:  2018-06-07       Impact factor: 3.575

Review 6.  The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options.

Authors:  Rebekah R White; James D Murphy; Robert C G Martin
Journal:  Ann Surg Oncol       Date:  2021-02-14       Impact factor: 5.344

7.  Normal and fibrotic liver parenchyma respond differently to irreversible electroporation.

Authors:  Chenang Lyu; Maya Lopez-Ichikawa; Boris Rubinsky; Tammy T Chang
Journal:  HPB (Oxford)       Date:  2019-03-14       Impact factor: 3.647

8.  Safety and efficacy of magnetic anchoring electrode-assisted irreversible electroporation for gastric tissue ablation.

Authors:  Fenggang Ren; Qingshan Li; Liangshuo Hu; Xiaopeng Yan; Zhongyang Gao; Jing Zhang; Weiman Gao; Zhe Zhang; Pengkang Chang; Xue Chen; Dake Chu; Rongqian Wu; Yi Lv
Journal:  Surg Endosc       Date:  2019-04-22       Impact factor: 4.584

9.  Perioperative systemic immunophenotype following irreversible electroporation (IRE) predicts recurrence.

Authors:  Conor H O'Neill; Min Tan; Jun Yan; Yan Li; Robert C G Martin
Journal:  Am J Cancer Res       Date:  2022-01-15       Impact factor: 6.166

10.  Technique, safety, and feasibility of EUS-guided radiofrequency ablation in unresectable pancreatic cancer.

Authors:  Filippo Scopelliti; Antonio Pea; Rita Conigliaro; Giovanni Butturini; Isabella Frigerio; Paolo Regi; Alessandro Giardino; Helga Bertani; Marina Paini; Paolo Pederzoli; Roberto Girelli
Journal:  Surg Endosc       Date:  2018-05-15       Impact factor: 4.584
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.